Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related Genes

23 Jan 2024

Abstract excerpt

Genome-wide association studies and candidate gene association studies have identified more than 180 genetic variants statistically associated with anthracycline-induced cardiotoxicity (AIC). However, the lack of functional validation has hindered the clinical translation of these findings. The aim of this study was to functionally validate all genes associated with AIC using human induced pluripotent stem...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiac electrophysiology and arrhythmias
Share to Chemotherapy-induced cardiotoxicity and mitigation
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38510289
DOI: 10.1016/j.jaccao.2023.11.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related GenesPMID 38510289Read ↗

Genome-wide CRISPR/Cas9 screening in human iPS derived cardiomyocytes uncovers novel mediators of doxorubicin cardiotoxicity.Semantic proximity Read ↗

Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-CardiomyocytesSemantic proximity Read ↗

Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.Semantic proximity Read ↗

Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity.Semantic proximity Read ↗

Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity.Semantic proximity Read ↗

Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessmentSemantic proximity Read ↗

Understanding the Mechanisms of Chemotherapy-Related Cardiotoxicity Employing hiPSC-Derived Cardiomyocyte Models for Drug Screening and the Identification of Genetic and Epigenetic VariantsSemantic proximity Read ↗

A non-coding GWAS variant impacts anthracycline-induced cardiotoxic phenotypes in human iPSC-derived cardiomyocytes.Semantic proximity Read ↗

Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?Semantic proximity Read ↗

Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.Semantic proximity Read ↗

Personalized medicine in cardio-oncology: the role of induced pluripotent stem cellSemantic proximity Read ↗

predicTox: An integrated database of clinical risk frequencies and human gene expression signatures for cardiotoxic drugsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.